Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern.

  • Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE:PFE) - BioNTech SE's (NASDAQ:BNTX) Comirnaty immunization, demonstrated robust antibody responses.
  • Related: Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs.
  • Neutralizing antibody concentrations were maintained between 15 and 29 days post-administration. 
  • These results are expected to support further clinical development of these candidates as booster vaccines.
  • Price Action: ARCT shares are down 6.47% at $23.00 during the premarket session on Monday's last check.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.